Akzo Nobel Valuation
Is AKZA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AKZA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AKZA (€56.3) is trading below our estimate of fair value (€141.61)
Significantly Below Fair Value: AKZA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AKZA?
Key metric: As AKZA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is AKZA's PE Ratio? | |
|---|---|
| PE Ratio | 17x |
| Earnings | €565.00m |
| Market Cap | €9.61b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 10.7x |
| PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does AKZA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.6x | ||
CRBN Corbion | 15.8x | 8.7% | €1.3b |
APAM Aperam | 7.1x | 7.6% | €2.0b |
002001 Zhejiang NHU | 14.9x | 9.3% | CN¥68.1b |
6988 Nitto Denko | 12.4x | 2.1% | JP¥1.7t |
AKZA Akzo Nobel | 17x | 12.0% | €9.6b |
Price-To-Earnings vs Peers: AKZA is expensive based on its Price-To-Earnings Ratio (17x) compared to the peer average (12.5x).
Price to Earnings Ratio vs Industry
How does AKZA's PE Ratio compare vs other companies in the European Chemicals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: AKZA is good value based on its Price-To-Earnings Ratio (17x) compared to the European Chemicals industry average (17.9x).
Price to Earnings Ratio vs Fair Ratio
What is AKZA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 17x |
| Fair PE Ratio | 18.4x |
Price-To-Earnings vs Fair Ratio: AKZA is good value based on its Price-To-Earnings Ratio (17x) compared to the estimated Fair Price-To-Earnings Ratio (18.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €56.30 | €73.58 +30.7% | 10.7% | €91.00 | €58.00 | n/a | 19 |
| Nov ’25 | €59.10 | €73.47 +24.3% | 10.5% | €91.00 | €58.00 | n/a | 19 |
| Oct ’25 | €62.44 | €73.53 +17.8% | 12.6% | €91.00 | €54.00 | n/a | 19 |
| Sep ’25 | €57.70 | €72.89 +26.3% | 13.6% | €91.00 | €53.00 | n/a | 18 |
| Aug ’25 | €56.20 | €73.06 +30.0% | 13.3% | €91.00 | €53.00 | n/a | 18 |
| Jul ’25 | €56.18 | €75.94 +35.2% | 13.4% | €94.00 | €53.00 | n/a | 18 |
| Jun ’25 | €64.14 | €78.28 +22.0% | 9.7% | €94.00 | €65.00 | n/a | 18 |
| May ’25 | €62.14 | €78.39 +26.1% | 9.8% | €94.00 | €65.00 | n/a | 18 |
| Apr ’25 | €69.18 | €78.64 +13.7% | 10.7% | €96.00 | €63.00 | n/a | 18 |
| Mar ’25 | €67.84 | €79.08 +16.6% | 9.7% | €96.00 | €65.00 | n/a | 18 |
| Feb ’25 | €71.02 | €79.61 +12.1% | 10.9% | €96.00 | €65.00 | n/a | 19 |
| Jan ’25 | €74.82 | €79.05 +5.7% | 13.2% | €100.00 | €60.00 | n/a | 19 |
| Dec ’24 | €71.14 | €79.42 +11.6% | 13.2% | €100.00 | €60.00 | n/a | 19 |
| Nov ’24 | €63.40 | €80.89 +27.6% | 12.0% | €100.00 | €60.00 | €59.10 | 19 |
| Oct ’24 | €68.48 | €83.29 +21.6% | 8.6% | €94.00 | €68.50 | €62.44 | 19 |
| Sep ’24 | €75.08 | €82.82 +10.3% | 10.1% | €100.00 | €68.50 | €57.70 | 19 |
| Aug ’24 | €77.44 | €82.61 +6.7% | 10.1% | €100.00 | €68.50 | €56.20 | 19 |
| Jul ’24 | €74.72 | €82.21 +10.0% | 11.0% | €100.00 | €63.00 | €56.18 | 19 |
| Jun ’24 | €71.50 | €80.33 +12.3% | 15.6% | €100.00 | €42.52 | €64.14 | 20 |
| May ’24 | €75.14 | €79.20 +5.4% | 15.5% | €100.00 | €42.52 | €62.14 | 20 |
| Apr ’24 | €71.98 | €76.60 +6.4% | 16.5% | €100.00 | €42.52 | €69.18 | 20 |
| Mar ’24 | €69.24 | €76.68 +10.7% | 16.4% | €100.00 | €42.52 | €67.84 | 20 |
| Feb ’24 | €68.88 | €75.58 +9.7% | 16.6% | €100.00 | €42.52 | €71.02 | 20 |
| Jan ’24 | €62.56 | €78.79 +25.9% | 18.3% | €110.00 | €42.52 | €74.82 | 21 |
| Dec ’23 | €67.40 | €78.79 +16.9% | 18.4% | €110.00 | €42.52 | €71.14 | 21 |
| Nov ’23 | €62.52 | €78.99 +26.3% | 19.0% | €110.00 | €42.83 | €63.40 | 21 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Corbion
€1.3b
Provides lactic acid and lactic acid derivatives, other ferment, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide.
CRBN
€21.76
7D
-4.3%
1Y
22.9%
Hydratec Industries
€207.7m
Through its subsidiaries, manufactures and sells industrial systems and plastic components for food, health, and mobility markets in the Netherlands, rest of Europe, Asia, North America, South America, Africa, and Oceania.
HYDRA
€160.00
7D
0.6%
1Y
79.8%
DSM-Firmenich
€27.2b
Provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia.
DSFIR
€102.45
7D
-2.8%
1Y
11.4%